Quince Therapeutics, Inc. (IRLA) SEC Filings & Earnings Calls

Clinical development risk remains high; no new derisking events.

“Risks related to clinical development and regulatory approval of the company's product candidates, including potential delays.” · word for word

Clinical-stage biotech with no approved products; pipeline risk.

“Company is clinical stage, LAM-001 in Phase 2 trials; no approved therapies.”

Potential dilution from equity plans and conversion of Series C Preferred Stock.

“2026 Plan initial reserve of 821,872 shares plus up to 1,377,845 shares from prior plans; ESPP initial reserve of 142,045 shares; conversion of Series C Preferred Stock may result in issuance of shares representing >20% of outstanding common stock.”

Board instability and potential change of control risk due to conditional resignations and appointments tied to stockholder approval of conversion and share increase.

“Resignations and appointments are conditional on approval of proposals that may result in change of control per Nasdaq rules.”

Sale of core AIDE/eDSP assets for nominal cash suggests abandonment of key pipeline; CEO departure adds leadership uncertainty.

“sale of ... AIDE technology ... for the treatment of Ataxia-Telangiectasia ... to Ayma Therapeutics, Inc. ... Ayma paid $450,000 in cash” · word for word

Delisting risk due to negative equity; potential loss of Nasdaq listing and associated liquidity/visibility.

“received a written notification from Nasdaq notifying the Company that...stockholders' equity was ($35,324,000)...not in compliance with Nasdaq Listing Rule 5450(b)(1)(A)”

Leadership vacuum: President departing without named successor may disrupt operations and strategy.

“Departure of President Charles Ryan; no successor mentioned.”

Change of Control Risk

“may, together with certain changes to management and our Board, result in a change of control of the Company pursuant to Nasdaq Listing Rule 5635(b)” · word for word

Dilution Risk

“authorized shares increased from 250,000,000 to 275,000,000”

Dilution risk from conversion of preferred stock and warrants

“issuance of shares representing more than 20% of common stock outstanding”

Clinical trial failure risk

“We recognized a total impairment charge of $67.8 million for indefinite and finite-lived intangible assets for the six months ended June 30, 2026 related to the negative outcome of the NEAT study.” · word for word

Going concern / capital need

“We will need substantial additional funding to complete the development of our product candidates. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.” · word for word

Clinical-stage biotech with no approved products; pipeline risk and reliance on LAM-001 success.

“LAM-001 is investigational; Phase 2b data not expected until Q1 2028; significant net loss and cash burn.”

High G&A expense due to acquisition and restructuring; potential for continued elevated costs.

“G&A expense increased to $16.6M from $3.3M YoY due to $9.1M stock compensation and $4.4M professional fees.”

Leadership transition risk; integration of new management from acquired company may cause disruption.

“Conditional resignations of CEO and COO; new appointments from Orphai.”

Going concern uncertainty

“we concluded that substantial doubt exists with respect to our ability to continue as a going concern within one year after the date that these consolidated financial statements are issued” · word for word

No revenue or product candidates

“We have no other current product candidates and do not have sufficient resources to pursue further research and development activities.” · word for word

Dilution risk from equity financing

“If we raise additional funds by issuing equity securities, our stockholders will experience dilution.” · word for word

Nasdaq Delisting Risk

“on March 16, 2026, Nasdaq notified us that the bid price of our common stock had closed below the required $1.00 per share for 30 consecutive trading days” · word for word

Market Value of Listed Securities Below Requirement

“on March 17, 2026, we received a notice from Nasdaq that the market value of our listed securities ('MVLS') for the last 30 consecutive business days was less than the $50,000,000 required for continued listing” · word for word

Phase 3 trial failure eliminates lead asset

“In the NEAT study, the primary endpoint, which measured the change from baseline to last efficacy visit at month six using the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo, did not reach statistical significance.” · word for word

Substantial doubt about going concern

“Based on our available cash resources and current operating plan, there is substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that our financial statements for the year ended December 31, 2025 are issued.” · word for word

Nasdaq delisting risk

“In March 2026, we received notices from Nasdaq indicating that we are no longer in compliance with Nasdaq’s continued listing requirements relating to maintaining (i) a minimum bid price of our common stock equal to $1.00 per share” · word for word

No revenue or pipeline

“We have no other current product candidates and do not have sufficient resources to pursue further research and development activities at this time.” · word for word

Failed clinical trial eliminates pipeline; no revenue or operations.

“Our lead drug candidate, eDSP, did not meet primary or secondary endpoints in the NEAT clinical trial and we do not have resources to pursue further operations.” · word for word

Nasdaq delisting risk due to non-compliance with listing standards.

“Nasdaq may delist our securities from its exchange, which could adversely affect our ability to execute a strategic transaction and limit our stockholders’ liquidity.” · word for word

Reverse merger may not materialize; liquidation risk.

“If we are unsuccessful in engaging in a reverse merger, we will need to liquidate our business and you will not realize any return on an investment in our common stock.” · word for word

Going concern uncertainty

“we concluded that substantial doubt exists with respect to our ability to continue as a going concern within one year after the date that these unaudited condensed consolidated financial statements are issued.” · word for word

Dilution risk from equity financing

“If we raise additional funds by issuing equity securities, our stockholders will experience dilution.” · word for word

Clinical trial risk: topline results not yet available; pivotal data expected Q1 2026

“Topline results from Phase 3 NEAT expected Q1 2026”